Skip to content

Biocubik

Active
Private limited companyfounded 2022active for 4 yearsRue du Bois St-Jean 29, 4102 Seraing, BelgiumKBO/BCE: BE 0782.955.294
Summary

The annual accounts of Biocubik for financial year 2025 show a net loss of 250% of the equity at the start of that year. The 2025 annual accounts show equity of €500,040 and a net result of -€48,134. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 78% of 241 sector peers (NACE 72, financial year 2025). The company has been active since 2022 and the Belgian Official Gazette contains no insolvency or warning signals. The computed 12-month bankruptcy probability is 0.1% (very low).

Overview

Activity
Research and development on biotechnology
NACE 72101
1 site
Size
€592,794total assets 2025
Staff
1.9 FTE
Equity
€500,040
Loss
-€48,134
Net result +68%: other schema
Financial health
57 Fair Checked score 2025
Bankruptcy probabilitywithin 12 months
0.1%
Structure
Accounts 81 days early0 of 4 deeds read
Why 57raises riskCapped at 59: a net loss of at least half of total assets or of the equity at the start of the financial yearLoss of €48,134, the second in a row (financial year 2025)lowers riskLiquidity: current ratio 6.32, cash €182,578Sector: Scientific research and development (NACE 72)Equity €500,040 (84.4% of total assets)Show the evidence

Checked score

Score 2025
57 / 100
Fair
Probability in this band: 1.5% to 4.2%
Financially better than 70% of its sector peers (NACE 72, micro)
A net loss of at least half of total assets or of the equity at the start of the financial year caps the score at 59. Every signal that counts is listed under Signals.
Financial strength · tick = 2024
Strong
Solvency 100+60
equity 84.4% of total assets
Liquidity 86-3
short-term debt 13.5% · cash 30.8%
Profitability 9+9
return on assets -8.1%
Bankruptcy probability, 12 months
0.1% Very low
0%0.5%1.5%4%10%≥ 25%

Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.1% (936 companies, NACE 72, micro)
Last 24 months 11-2024: 0.1% 12-2024: 0.1%● unchanged vs 11-2024 01-2025: 0.1%● unchanged vs 12-2024 02-2025: 0.1%● unchanged vs 01-2025 03-2025: 0.1%● unchanged vs 02-2025 04-2025: 0.2%▲ +0.1 percentage points vs 03-2025 05-2025: 0.2%● unchanged vs 04-2025 06-2025: 0.2%● unchanged vs 05-2025highest value 07-2025: 0.2%● unchanged vs 06-2025highest value 08-2025: 0.2%● unchanged vs 07-2025highest value 09-2025: 0.2%● unchanged vs 08-2025highest value 10-2025: 0.2%● unchanged vs 09-2025highest value 11-2025: 0.2%● unchanged vs 10-2025 12-2025: 0.2%● unchanged vs 11-2025 01-2026: 0.2%● unchanged vs 12-2025 02-2026: 0.2%● unchanged vs 01-2026 03-2026: 0.2%● unchanged vs 02-2026 04-2026: 0.2%● unchanged vs 03-2026 05-2026: 0.2%● unchanged vs 04-2026 06-2026: 0.1%▼ -0.1 percentage points vs 05-2026lowest value 07-2026: 0.1%● unchanged vs 06-2026 08-2026: 0.1%● unchanged vs 07-2026 09-2026: 0.1%● unchanged vs 08-2026 10-2026: 0.1%● unchanged vs 09-2026
Credit of up to €25,000 on 30-day terms, only on tighter conditions
Net loss of at least half of total assets or of the equity at the start of the financial year.
Liquidity ample (current ratio 6.32, compared with 3.58 in 2024; short-term debt: 13.5% and cash: 30.8% of total assets), and 15.6% of the assets are financed with debt.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 72, micro): better than 83% on solvency, 74% on liquidity, 24% on profitability and 99% on growth.

The bankruptcy probability was computed on 09-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Six signals.
−lowers risk+raises risk○neutral
lowers risk · Liquidity: current ratio 6.32, cash €182,578
NBB · annual accounts
lowers risk · Sector: Scientific research and development (NACE 72)
KBO
raises risk · Loss of €48,134, the second in a row (financial year 2025)
NBB · annual accounts
lowers risk · Equity €500,040 (84.4% of total assets)
NBB · annual accounts
lowers risk · Growing equity
Reported equity is higher than in 2023 and did not fall compared with 2024. These amounts do not establish the cause of the change.
NBB · annual accounts 2025
Equity per financial year
22232425
2022 to 2025 · latest year €500,040
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 11-05-2026, 81 days ahead of the deadline.
NBB · 4 filings
Deviation from the deadline
2025
81 days early
2024
136 days early
2023
107 days early
2022
130 days early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 4 accounts on average 114 days before the deadline; the sector median (NACE 72) for financial year 2024 is 13 days before the deadline, and 32% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 4 April (3 of the last 4 filed years within 30 days of that day).
Companies Code · seven months
Where today falls in the filing period
09-10-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
Searched since incorporation in 2022.
KBO publications · our coverage
  1. Annual accounts filedfinancial year 2025 · full…
  2. Equity above €500,000equity €500,040 ▲2,498%
  3. Annual accounts filedfinancial year 2024 · micro…

Key points

  • Risk: 4 loss-making years in a rowloss financial year 2025 -€48,134 View
  • Positive: Equity rose in 2025from €19,248 to €500,040 ▲ 2,498% View
  • Positive: Always filed on timeaccounts within the deadline every year 4 years View

By topic

Financials

Financial year
2025
Total assets
€592,794
Loss
-€48,134
Solvency
84.4%
Total assets▲ 372%
Net result
20222025
Go to Financials

Timeline

Events
6
Since
2023
Next accounts
by 31-07-2027
  1. 31-12-2024Weakest financial year
  2. 15-04-2024Annual accounts filed
  3. 23-03-2023Annual accounts filed
Go to Timeline

Company details

Sites
1
Legal form
Private limited company
Activity
Research and development on biotechnologyNACE 72101
Founded
07-03-2022
Year ends
31-12
Peppol
Reachable for e-invoices
Go to Company details

Go further with this company

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.